WO1998029141A1 - Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes - Google Patents
Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes Download PDFInfo
- Publication number
- WO1998029141A1 WO1998029141A1 PCT/US1997/023904 US9723904W WO9829141A1 WO 1998029141 A1 WO1998029141 A1 WO 1998029141A1 US 9723904 W US9723904 W US 9723904W WO 9829141 A1 WO9829141 A1 WO 9829141A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrophobic
- hydrophilic
- dry powder
- component
- spray drying
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D1/00—Evaporating
- B01D1/16—Evaporating by spraying
- B01D1/18—Evaporating by spraying to obtain dry solids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
- B01J2/04—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a gaseous medium
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
- Y10S977/783—Organic host/matrix, e.g. lipid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/827—Nanostructure formed from hybrid organic/inorganic semiconductor compositions
- Y10S977/829—Organic or biological core coated with inorganic shell
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/882—Assembling of separate components, e.g. by attaching
- Y10S977/884—Assembled via biorecognition entity
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/89—Deposition of materials, e.g. coating, cvd, or ald
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
Definitions
- the present invention relates generally to dry powder compositions and methods for their preparation and use.
- the present invention relates to methods for spray drying pharmaceutical and other compositions comprising a hydrophobic drug or other component and a hydrophilic excipient or other component.
- Pulmonary drug delivery can itself be achieved by different approaches, including liquid nebulizers, aerosol- based metered dose inhalers (MDI's), and dry powder dispersion devices. Aerosol-based MDI's are losing favor because they rely on the use of chlorofluorocarbons (CFC's), which are being banned because of their adverse effect on the ozone layer. Dry powder dispersion devices, which do not rely on CFC aerosol technology, are promising for delivering drugs that may be readily formulated as dry powders.
- CFC's chlorofluorocarbons
- a particularly promising approach for the pulmonary delivery of dry powder drugs utilizes a hand-held device with a hand pump for providing a source of pressurized gas.
- the pressurized gas is abruptly released through a powder dispersion device, such as a venturi nozzle, and the dispersed powder made available for patient inhalation.
- a powder dispersion device such as a venturi nozzle
- the dispersed powder made available for patient inhalation.
- hand-held devices are problematic in a number of other respects.
- the particles being delivered are usually less than 5 ⁇ m in size, making powder handling and dispersion more difficult than with larger particles.
- the problems are exacerbated by the relatively small volumes of pressurized gas, which are available using hand-actuated pumps.
- venturi dispersion devices are unsuitable for difficult-to-disperse powders when only small volumes of pressurized gas are available with the handpump.
- Another requirement for hand-held and other powder delivery devices is efficiency.
- High device efficiency in delivering the drug to the patient with the optimal size distribution for pulmonary delivery is essential for a commercially viable product.
- Spray drying is a conventional chemical processing unit operation used to produce dry particulate solids from a variety of liquid and slurry starting materials.
- the use of spray drying for the formulation of dry powder pharmaceuticals is known, but has usually been limited to spray drying of hydrophilic drugs in aqueous solutions, usually in combination with hydrophilic excipients. Many drugs, however, are hydrophobic, preventing spray drying in aqueous solutions. While spray drying of hydrophobic materials can often be accomplished using an organic solvent, the use of such non- aqueous solvents generally limits the ability to simultaneously spray dry a hydrophilic excipient .
- hydrophobic and hydrophilic components such as hydrophobic drugs and hydrophilic excipients.
- spray drying methods should be compatible with a wide variety of hydrophobic drugs as well as conventional hydrophilic excipients, such as povidone (polyvinylpyrrolidone) and other water soluble polymers, mannitol and other water soluble carbohydrates, and particularly with those excipients which are accepted for use in inhalation formulations, such as lactose and sodium chloride.
- Such spray drying methods will preferably produce particles having a uniform size distribution, with a mean particle size below 10 ⁇ m, preferably below 5 ⁇ m, and a standard deviation less than or equal to ⁇ 2 ⁇ m. Such powders should further exhibit uniform composition from batch to batch so that any tendency for particles of different compositions and/or sizes to separate in the lungs will have a reproducible impact on the therapeutic effect. Additionally, such spray drying methods should provide for dry powders which are physically and chemically stable and which have low levels of any residual organic solvents or other components which might be used in the spray drying process. At least some of the above objectives will be met by the various embodiments of the present invention which are described in detail below. 2. Description of the Background Art
- WO 96/09814 describes spray dried pharmaceutical powders.
- Example 7 describes spray drying budesonide and lactose in ethanol where the budesonide is partially soluble and the lactose is insoluble.
- U.S. Patent Nos. 5,260,306; 4,590,206; GB 2 105 189; and EP 072 046 describe a method for spray drying nedocromil sodium to form small particles preferably in the range from 2 to 15 ⁇ m for pulmonary delivery.
- U.S. Patent No. 5,376,386, describes the preparation of particulate polysaccharide carriers for pulmonary drug delivery, where the carriers comprise particles sized from 5 to 1000 ⁇ m. Mumenthaler et al . (1994) Pharm . Res .
- WO 95/23613 describes preparing an inhalation powder of DNase by spray drying using laboratory-scale equipment.
- WO 91/16882 describes a method for spray drying proteins and other drugs in liposome carriers.
- the spray drying methods of the present invention permit the simultaneous spray drying of the hydrophobic component with a hydrophilic component, such as a hydrophilic pharmaceutical excipient, under conditions which result in a dry powder comprising mixtures of both the hydrophilic and hydrophobic components .
- the methods of the present invention are particularly useful for forming pharmaceutical compositions where the hydrophobic component is a hydrophobic drug, usually present at from 0.01% to 95% of the powder, and the hydrophilic component is a hydrophilic excipient, usually present at from 99.99% to 5% of the powder, the methods may be applied more broadly to form dry powders comprising a variety of hydrophobic and hydrophilic components at different concentration ranges, including hydrophilic drugs and hydrophobic excipients.
- the spray drying methods of the present invention are compatible with many hydrophilic pharmaceutical excipients, particularly including mannitol, povidone, lactose and sodium chloride. Use of the latter two excipients is particularly preferred for powders intended for pulmonary delivery as they are "generally recognized as safe” (GRAS) for such applications.
- hydrophilic pharmaceutical excipients particularly including mannitol, povidone, lactose and sodium chloride.
- the methods are also suitable for use with numerous hydrophobic drugs and nutrients, including steroids and their salts, such as budesonide, testosterone, progesterone, estrogen, flunisolide, triamcinolone, beclomethasone, betamethasone; dexamethasone, fluticasone, methylprednisolone, prednisone, hydrocortisone, and the like; peptides, such as cyclosporin and other water insoluble peptides; retinoids, such as all-cis retinoic acid, 13 -trans retinoic acid, and other vitamin A and beta carotene derivatives; vitamins D, E, and K and water insoluble precursors and derivatives thereof; prostagladins and leukotrienes and their activators and inhibitors including prostacyclin (epoprostanol) , prostaglandins E E 2 , tetrahydrocannabinol; lung surfactant lipids; lipid soluble antioxidants; hydropho
- the spray drying methods can produce a uniform particle size distribution.
- the mean particle diameter can be controlled below 10 ⁇ m, preferably below 5 ⁇ m, with a size distribution (standard deviation) less than ⁇ 2 ⁇ m.
- the particles of the powders so produced have a minimum batch-to-batch variability in composition, and are physically and chemically stable.
- the powders have minimum residual organic solvents to the extent they may have been used in the spray drying process .
- the method of the present invention comprises at least partially dissolving hydrophilic component in an organic solvent or cosolvent system.
- the hydrophobic component is at least partially dissolved in the same organic solvent or cosolvent system to produce a solution.
- the organic solvent solution or cosolvent system is then spray dried to form particles comprising a mixture of the hydrophilic and hydrophobic components.
- the organic solvent will be selected to provide a solubility for the hydrophilic component of at least 1 mg/ml, preferably at least 5 mg/ml, and a solubility for the hydrophobic component of at least 0.01 mg/ml, preferably at least 0.05 mg/ml.
- the hydrophilic component will have a concentration in the organic solvent or cosolvent system solution from 1 mg/ml to 100 mg/ml, preferably from 5 mg/ml to 60 mg/ml, and the hydrophobic component will have a concentration from 0.01 mg/ml to 10 mg/ml, preferably from 0.05 mg/ml to 5 mg/ml.
- Suitable organic solvents or solvent systems are selected to provide such minimum solubility characteristics, but it is preferred if the organic solvent or cosolvent system provides solubilities well in excess of the stated minimums .
- the use of a nonaqueous solution will be advantageous for spray drying components that are physically or chemically sensitive to either water while in solution or to residual moisture content in the powder.
- a presently preferred cosolvent system comprises water :ethanol at a weight ratio in the range from 80:20 to 20:80, usually from 40:60 to 60:40, preferably 50:50.
- the utilization of a water : ethanol system is preferred for any hydrophobic component and hydrophilic component combination which has adequate solubility and stability in this solvent system, due to the low worker exposure toxicological hazard posed by this solvent system, and because of the lack of toxicity of any residual solvent in the powder after spray drying is complete.
- Powders prepared by the above method will be collected from the spray drier in a conventional manner for subsequent use.
- the dry powder formulations will usually be measured into a single dose, and the single dose sealed into a package.
- Such packages are particularly useful for dispersion in dry powder inhalers, as described in detail below.
- the powders may be packaged in multiple-dose containers.
- the present invention further comprises dry powder compositions produced according to the methods described above, as well as unit dose and multidose packages of such dried powder compositions containing a therapeutically effective amount of the dry powder.
- the present invention further provides methods for aerosolizing a dry powder composition comprising the steps of providing an amount of dry powder composition produced by any of the methods described above and subsequently dispersing the dry powder composition into a flowing gas stream.
- FIG. 1 is a block diagram illustrating a spray drying system suitable for performing the methods of the present invention.
- the present invention relates to methods for preparing compositions comprising ultrafine dry powders having both hydrophobic and hydrophilic components.
- the methods are particularly suitable for producing ultrafine pharmaceutical dry powders where the hydrophobic component is a hydrophobic drug and the hydrophilic component is a hydrophilic excipient.
- the present invention may find use for preparing a variety of other compositions including pharmaceutical compositions having hydrophilic drugs and hydrophobic excipients and compositions intended for non-pharmaceutical applications.
- the methods rely on spray drying liquid media in which the components are solubilized or suspended.
- an organic solvent or cosolvent system is selected which can solubilize both the hydrophobic and the hydrophilic component .
- hydrophobic component refers to materials which are insoluble or sparingly or poorly soluble in water. As used herein, such compositions will have a solubility below 5 mg/ml, usually below 1 mg/ml.
- exemplary hydrophobic drugs include certain steroids, such as budesonide, testosterone, progesterone, estrogen, flunisolide, triamcinolone, beclomethasone, betamethasone; dexamethasone, fluticasone, methylprednisolone, prednisone, hydrocortisone, and the like; certain peptides, such as cyclosporin cyclic peptide, retinoids, such as all-cis retinoic acid, 13-trans retinoic acid, and other vitamin A and beta carotene derivatives; vitamins D, E, and K and water insoluble precursors and derivatives thereof; prostagladins and leukotrienes and their activators and inhibitors including prostacyclin (epoprostanol)
- hydrophilic component it is meant that the component is highly soluble in water and frequently capable of swelling and formation of reversible gels. Typical aqueous solubilities of hydrophilic components will be greater than 5 mg/ml, usually greater than 50 mg/ml, and often much higher.
- the pharmaceutical excipients will generally be selected to provide stability, dispersibility, consistency and/or bulking characteristics to enhance the uniform pulmonary delivery of the dried powder composition to a patient. For pulmonary delivery, the excipients must be capable of being taken into the lungs with no significant adverse toxicological effects on the lungs.
- hydrophilic excipients include carbohydrates and other materials selected from the group consisting of lactose, mannitol, povidone, sodium chloride, water soluble polymers, and the like. Particularly preferred are lactose and sodium chloride which are generally accepted for pulmonary delivery in dry powder formulations.
- ultrason dry powder means a powder composition comprising a plurality of discrete, dry particles having the characteristics set forth below.
- the dry particles will have an average particle size below 10 ⁇ m, usually below 5 ⁇ m, preferably being in the range from 0.4 to 5 ⁇ m, more preferably from 0.4 to 4 ⁇ m.
- the average particle size of the powder will be measured as mass median diameter (MMD) by conventional techniques.
- a particular powder sizing technique uses a centrifugal sedimentary particle size analyzer (Horiba Capa 700) .
- the powders will be capable of being readily dispersed in an inhalation device and subsequently inhaled by a patient so that the particles are able to penetrate into the alveolar regions of the lungs.
- the ultrafine dry particle compositions produced by the method will have particle size distributions which enable them to target the alveolar region of the lung for pulmonary delivery of locally acting steroids, systemically acting proteins, and other biologically active materials that can be administered to or through the lungs.
- Such compositions advantageously may be incorporated into unit dosage and other forms without further size classification.
- the ultrafine dry powders will have a size distribution where at least 90% of the powder by weight will comprise particles having an average size in the range from 0.1 ⁇ m to 7 ⁇ m, with preferably at least 85% being in the range from 0.4 ⁇ m to 5 ⁇ m. Additionally, it is desirable that the particle size distribution avoid having an excess amount of particles with very small average diameters, i.e., below 0.4 ⁇ m.
- dry means that the particles of the powder have a moisture content such that the powder is physically and chemically stable in storage at room temperature and is readily dispersible in an inhalation device to form an aerosol.
- the moisture and residual solvent content of the particles is below 10% by weight, usually being below 5% by weight, preferably being below 3% by weight, or lower.
- the moisture and residual solvent content will usually be controlled by the drying conditions, as described in more detail below.
- dry further means that the particles of the powder have a moisture and residual solvent content such that the powder is readily dispersible in an inhalation device to form an aerosol. In some cases, however, non-aqueous medium may be used for dispersing the components, in which case the aqueous content may approach zero.
- therapeutically effective amount is the amount present in the composition that is needed to provide the desired level of hydrophobic drug in the subject to be treated to give the anticipated physiological response. This amount is determined for each drug on a case-by-case basis.
- physiologically effective amount is that amount delivered to a subject to give the desired palliative or curative effect. This amount is specific for each drug and its ultimate approval dosage level.
- the therapeutically effective amount of hydrophobic drug will vary in the composition depending on the biological activity of the drug employed and the amount needed in a unit dosage form. Because the subject powders are dispersible, it is highly preferred that they be manufactured in a unit dosage form in a manner that allows for ready manipulation by the formulator and by the consumer.
- a unit dosage will be between about 0.5 mg and 15 mg of total material in the dry powder composition, preferably between about 1 mg and 10 mg.
- the amount of hydrophobic drug in the composition will vary from about 0.01% w/w to about 95% w/w. Most preferably the composition will be about 0.05% w/w to about 25% w/w drug.
- processes according to the present invention for preparing dispersible dry powders of hydrophobic and hydrophilic components comprise an atomization operation 10 which produces droplets of a liquid medium which, are dried in a drying operation 20. Drying of the liquid droplets results in formation of the discrete particles which form the dry powder compositions which are then collected in a separation operation 30.
- atomization operation 10 which produces droplets of a liquid medium which, are dried in a drying operation 20. Drying of the liquid droplets results in formation of the discrete particles which form the dry powder compositions which are then collected in a separation operation 30.
- the atomization process 10 may utilize any one of several conventional forms of atomizers.
- the atomization process increases the surface area of the starting liquid. Due to atomization there is an increase in the surface energy of the liquid, the magnitude of which is directly proportional to the surface area increase. The source of this energy increase depends on the type of atomizer used. Any atomizer (centrifugal, sonic, pressure, two fluid) capable of producing droplets with a mass median diameter of less than about 20 ⁇ m could be used.
- Preferred for the present invention is the use of two fluid atomizers where the liquid medium is delivered through a nozzle concurrently with a high pressure gas stream. Particularly preferred is the use of two-fluid atomization nozzles as described in copending application serial no.
- the atomization gas will usually be nitrogen which has been filtered or otherwise cleaned to remove particulates and other contaminants. Alternatively, other gases, such as air may be used.
- the atomization gas will be pressurized for delivery through the atomization nozzle, typically to a pressure above 5 psig, preferably being above 10 psig.
- the drying operation 20 will be performed next to evaporate liquid from the droplets produced by the atomization operation 10.
- the drying will require introducing energy to the droplets, typically by mixing the droplets with a heated gas which causes evaporation of the water or other liquid medium.
- the heated gas stream will flow concurrently with the atomized liquid, but it would also be possible to employ counter-current flow, cross-current flow, or other flow patterns .
- the drying rate may be controlled based on a number of variables, including the droplet size distribution, the inlet temperature of the gas stream, the outlet temperature of the gas stream, the inlet temperature of the liquid droplets, and the manner in which the atomized spray and hot drying gas are mixed.
- the drying gas stream will have an inlet temperature of at least 70 °C.
- the outlet temperature will usually be at least about 40 °C.
- the drying gas will usually be air or nitrogen which has been filtered or otherwise treated to remove particulates and other contaminants.
- the gas will be moved through the system using conventional blowers or compressors.
- the separation operation 30 will be selected in order to achieve very high efficiency collection of the ultrafine particles produced by the drying operation 20.
- Conventional separation operations may be used, although in some cases they should be modified in order to assure collection of sub-micron particles.
- separation is achieved using a filter medium such as a membrane medium (bag filter) , a sintered metal fiber filter, or the like.
- separation may be achieved using cyclone separators, although it is usually desirable to provide for high energy separation in order to assure the efficient collection of sub-micron particles.
- the separation operation should achieve collection of at least 80% of all particles above 1 ⁇ m in average particle size, preferably being above 85%, more preferably being above 90%, and even more preferably being above 95%, in collection efficiency.
- a cyclone separator can be used to separate very fine particles, e.g. 0.1 ⁇ m, from the final collected particles.
- the cyclone operating parameters can be selected to provide an approximate cutoff where particles above about 0.1 ⁇ m are collected while particles below 0.1 ⁇ m are carried over in the overhead exhaust.
- the presence of particles below 0.1 ⁇ m in the pulmonary powder is undesirable since they will generally not deposit in the alveolar regions of the lungs, but instead will be exhaled.
- the present invention relies on proper selection of the liquid medium or media for solubilizing the hydrophobic drug or other component and hydrophilic excipient or other component.
- An organic solvent or cosolvent is selected in which both the hydrophobic drug or other component and the hydrophilic excipient or other component may be dissolved. Neither the drug nor excipient need be highly soluble in the solvent, since both components will typically be present in the solvent at relatively low concentrations, usually below 10% w/v, more usually below 5% w/v.
- the solvent must further be selected to leave minimum residual solvent in the spray dried product.
- the particular organic solvent or cosolvent selected will depend on the nature of the hydrophobic drug and the hydrophilic excipient. Suitable organic solvents or solvent systems may include an alcohol, ketone, hydrocarbon, polar aprotic solvent, or the like, and mixtures and aqueous solutions thereof.
- nonaqueous solution will be advantageous for spray drying components that are physically or chemically sensitive to either water while in solution or to residual moisture content in the powder.
- the utilization of a nonaqueous solution will essentially eliminate the exposure of the component to both water during spray drying and residual moisture in the powder, thereby avoiding triggering the component's sensitivity to water.
- Exemplary combinations of drug, excipient, and solvent are set forth in Table 1 below.
- a presently preferred cosolvent comprises water : ethanol in the ratios set forth above.
- the utilization of an ethanol/water system is preferred for any hydrophobic component and hydrophilic component combination which has adequate solubility and stability in this solvent system, due to the low worker exposure toxicological hazard posed by this solvent system, and because of the lack of toxicity of any residual solvent in the powder after spray drying is complete.
- This spray drying method which employs a common solubilizing solvent system, is advantageous in that both the hydrophobic drug or other component and the hydrophilic excipient or other component will be fully dissolved, enhancing product uniformity after spray drying.
- the full dissolution of the component is desirable since it greatly reduces the likelihood that the components will separate to any significant extent during storage, delivery to the spray drier, passage through the atomization nozzle, or during the spray drying operation.
- unit dosage forms may comprise a unit dosage receptacle containing a dry powder.
- the powder is placed within a suitable dosage receptacle in an amount sufficient to provide a subject with drug for a unit dosage treatment.
- the dosage receptacle is one that fits within a suitable inhalation device to allow for the aerosolization of the dry powder composition by dispersion into a gas stream to form an aerosol and then capturing the aerosol so produced in a chamber having a mouthpiece attached for subsequent inhalation by a subject in need of treatment.
- Such a dosage receptacle includes any container enclosing the composition known in the art such as gelatin or plastic capsules with a removable portion that allows a stream of gas (e.g., air) to be directed into the container to disperse the dry powder composition.
- a stream of gas e.g., air
- Such containers are exemplified by those shown in U.S. Patents 4,227,522 issued October 14, 1980; 4,192,309 issued March 11, 1980; and 4,105,027 issued August 8, 1978.
- Suitable containers also include those used in conjunction with Glaxo ' s Ventolin Rotohaler ® brand powder inhaler or Fison's Spinhaler ® brand powder inhaler.
- Another suitable unit-dose container which provides a superior moisture barrier is formed from an aluminum foil plastic laminate.
- the pharmaceutical-based powder is filled by weight or by volume into the depression in the formable foil and hermetically sealed with a covering foil-plastic laminate.
- a container for use with a powder inhalation device is described in U.S. patent 4,778,054 and is used with Glaxo ' s Diskhaler ® (U.S. Patents 4,627,432; 4,811,731; and 5,035,237).
- Preferred dry powder inhalers are those described in U.S. Patent application serial nos. 08/309,691 and 08/487,184, assigned to the assignee of the present invention. The latter application has been published as WO 96/09085.
- Budesonide (micronized to a median particle size of 1-2 ⁇ m; Steraloids)
- Lactose monohydrate (NF grade; Foremost Ingredient Group)
- DMSO Dimethyl sulfoxide
- Median particle size refers to the volume based particle size distribution of the prepared bulk powders determined via centrifugal sedimentation as follows. A sample of the powder was suspended in an appropriate liquid medium (one that minimizes solubilizing the particle) , sonicated to break up the agglomerates, and then centrifuged. The median particle size was determined by measuring the sedimentation rate during centrifugation. This method provides the median size of the "primary" particle, that is, the size of the particles produced by the manufacturing process, plus potential modification during sample preparation. Because these formulations are composed of both water soluble and water insoluble materials, it is likely that the suspension step during sample preparation does to some extent solubilize part of the particle, and thereby modify the particle size that is determined. Therefore, the resultant particle sizes should be viewed as estimated values, rather than absolute values. Moisture content was determined by the Karl -Fischer Reagent titrimetric method.
- Delivered dose efficiency refers to a measure of the percentage of powder which is drawn out of a blister package and which exits the mouthpiece of an inhaler device as described in U.S. Patent Application Serial No. 08/487,184.
- Delivered dose efficiency is a measure of efficiency for the powder package/device combination.
- the test was performed by connecting a vacuum system to the device mouthpiece.
- the vacuum system was set to be similar to a human inhalation with regard to volume and flow rate (1.2 liters total at 30 liters/minute) .
- a blister package containing 0.5 to 10 mg of the formulation to be evaluated (2 to 5 mg of powder was used for the following examples) was loaded into a device which was held in a testing fixture.
- the device was pumped and fired, and the vacuum "inhalation" was switched on.
- the aerosol cloud was thus drawn out of the device chamber by the vacuum, and the powder was collected on a filter placed between the mouthpiece and the vacuum source.
- the weight of the powder collected on the filter was determined. Delivered dose efficiency was calculated by multiplying this weight by one hundred and dividing by the fill weight in the blister. A higher number was a better result than a lower number.
- the indicated amounts of the budesonide and the excipient (s) were mixed with the indicated amount of the liquid medium until all of the solids were completely dissolved to form a solution. If necessary the solution was sonicated to fully dissolve the solids.
- the indicated amount of budesonide was dissolved in the indicated amount of ethanol with mixing
- the indicated amount of excipient (s) was dissolved in the indicated amount of water with mixing
- the two solutions were mixed together, resulting in a single solution containing all of the components.
- the solution was spray dried, and the resulting powder passed through a 35 mesh screen. This last step may not always be required, but it has been found that passing the powder through a screen will often decrease the delivered dose efficiency variability.
- Table 2 shows the spray drier atomization air pressure and outlet air temperature, the quantitative composition, a description of the particle morphology, the moisture content where water was a component in the liquid medium, particle size, and delivered dose efficiency for each powder. Where the powders were passed through a 35 mesh screen, the delivered dose efficiency results are preceded by the word "screened.” It is noteworthy that the use of a 1:2 DMSO/acetone liquid medium yielded low delivered dose efficiency results as did the formulation where sodium chloride was the sole excipient.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP53022598A JP2001507701A (en) | 1996-12-31 | 1997-12-29 | Method for spray drying a solution of a hydrophobic drug having a hydrophilic excipient and a composition made by the method |
EP97954240A EP0951300A4 (en) | 1996-12-31 | 1997-12-29 | Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
AU58069/98A AU5806998A (en) | 1996-12-31 | 1997-12-29 | Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3483796P | 1996-12-31 | 1996-12-31 | |
US60/034,837 | 1996-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998029141A1 true WO1998029141A1 (en) | 1998-07-09 |
Family
ID=21878919
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/023904 WO1998029141A1 (en) | 1996-12-31 | 1997-12-29 | Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
PCT/US1997/023905 WO1998029098A1 (en) | 1996-12-31 | 1997-12-29 | Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
PCT/US1997/023903 WO1998029140A1 (en) | 1996-12-31 | 1997-12-29 | Processes and compositions for spray drying hydrophobic drugs in organic solvent suspensions of hydrophilic excipients |
PCT/US1997/023902 WO1998029096A1 (en) | 1996-12-31 | 1997-12-29 | Aerosolized hydrophobic drug |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/023905 WO1998029098A1 (en) | 1996-12-31 | 1997-12-29 | Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
PCT/US1997/023903 WO1998029140A1 (en) | 1996-12-31 | 1997-12-29 | Processes and compositions for spray drying hydrophobic drugs in organic solvent suspensions of hydrophilic excipients |
PCT/US1997/023902 WO1998029096A1 (en) | 1996-12-31 | 1997-12-29 | Aerosolized hydrophobic drug |
Country Status (5)
Country | Link |
---|---|
US (6) | US6001336A (en) |
EP (3) | EP0971698A4 (en) |
JP (3) | JP2001507701A (en) |
AU (4) | AU5806898A (en) |
WO (4) | WO1998029141A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6315983B1 (en) | 1996-01-24 | 2001-11-13 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Process for the production of powdered pulmonary surfactant preparations |
US6630121B1 (en) | 1999-06-09 | 2003-10-07 | The Regents Of The University Of Colorado | Supercritical fluid-assisted nebulization and bubble drying |
US6669960B2 (en) | 1999-12-21 | 2003-12-30 | Rxkinetix, Inc. | Particulate drug-containing products and method of manufacture |
US6761909B1 (en) | 1999-12-21 | 2004-07-13 | Rxkinetix, Inc. | Particulate insulin-containing products and method of manufacture |
US10806770B2 (en) | 2014-10-31 | 2020-10-20 | Monash University | Powder formulation |
Families Citing this family (252)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6743777B1 (en) * | 1992-03-19 | 2004-06-01 | Eli Lilly And Company | Cyclic peptide antifungal agents and process for preparation thereof |
US6673335B1 (en) * | 1992-07-08 | 2004-01-06 | Nektar Therapeutics | Compositions and methods for the pulmonary delivery of aerosolized medicaments |
ATE220327T1 (en) * | 1992-09-29 | 2002-07-15 | Inhale Therapeutic Syst | PULMONARY RELEASE OF ACTIVE FRAGMENTS OF THE PARATHORMONE |
US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
EP0748213B1 (en) * | 1994-03-07 | 2004-04-14 | Nektar Therapeutics | Methods and compositions for pulmonary delivery of insulin |
US20030113273A1 (en) * | 1996-06-17 | 2003-06-19 | Patton John S. | Methods and compositions for pulmonary delivery of insulin |
ATE299892T1 (en) * | 1994-05-18 | 2005-08-15 | Nektar Therapeutics | METHODS AND COMPOSITIONS FOR DRY POWDER MEDICATION FROM INTERFERONS |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
US5944012A (en) * | 1996-03-25 | 1999-08-31 | Pera; Ivo E. | Method for dispensing antioxidant vitamins by inhalation background of the invention |
US20020052310A1 (en) * | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
EP0971698A4 (en) * | 1996-12-31 | 2006-07-26 | Nektar Therapeutics | Aerosolized hydrophobic drug |
US20030203036A1 (en) | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
GB9703673D0 (en) * | 1997-02-21 | 1997-04-09 | Bradford Particle Design Ltd | Method and apparatus for the formation of particles |
US20030035778A1 (en) * | 1997-07-14 | 2003-02-20 | Robert Platz | Methods and compositions for the dry powder formulation of interferon |
US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
GB9726916D0 (en) * | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
TW581681B (en) * | 1998-02-20 | 2004-04-01 | Nektar Therapeutics | Liquid crystal forms of cyclosporin |
PT1073417E (en) * | 1998-04-18 | 2003-04-30 | Glaxo Group Ltd | PHARMACEUTICAL FORMULA IN AEROSOL |
US6956021B1 (en) | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
US6234167B1 (en) | 1998-10-14 | 2001-05-22 | Chrysalis Technologies, Incorporated | Aerosol generator and methods of making and using an aerosol generator |
US6509005B1 (en) * | 1998-10-27 | 2003-01-21 | Virginia Commonwealth University | Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US6984404B1 (en) | 1998-11-18 | 2006-01-10 | University Of Florida Research Foundation, Inc. | Methods for preparing coated drug particles and pharmaceutical formulations thereof |
US20020006901A1 (en) * | 1999-02-05 | 2002-01-17 | Aldo T. Iacono | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
KR20020003864A (en) | 1999-03-03 | 2002-01-15 | 피터 지. 스트링거 | Echinocandin/carbohydrate complexes |
DE60019902D1 (en) * | 1999-03-03 | 2005-06-09 | Lilly Co Eli | ECHINOCANDIN PHARMACEUTICAL COMPOSITIONS |
DK1169019T3 (en) | 1999-04-14 | 2003-06-02 | Glaxo Group Ltd | Pharmaceutical aerosol formulation |
EP1175204A4 (en) * | 1999-05-04 | 2006-05-31 | Aradigm Corp | Aerosol formulations and devices for increasing libido in women via acute testosterone administration |
US7258850B2 (en) | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
US6428769B1 (en) * | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6610317B2 (en) | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6406745B1 (en) * | 1999-06-07 | 2002-06-18 | Nanosphere, Inc. | Methods for coating particles and particles produced thereby |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
ATE371490T1 (en) * | 1999-06-30 | 2007-09-15 | Nektar Therapeutics | METHOD AND SYSTEM FOR PRODUCING DRY POWDER USING SPRAY DRYING |
US7648696B2 (en) | 1999-08-20 | 2010-01-19 | Unimed Pharmaceuticals, Llc | Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent |
US6747058B1 (en) | 1999-08-20 | 2004-06-08 | Unimed Pharmaceuticals, Inc. | Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor |
WO2001013891A2 (en) * | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
US20010036481A1 (en) * | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
ES2254164T3 (en) * | 1999-10-29 | 2006-06-16 | Nektar Therapeutics | DRY POWDER COMPOSITIONS WITH IMPROVED DISPERSABILITY. |
US7304750B2 (en) | 1999-12-17 | 2007-12-04 | Nektar Therapeutics | Systems and methods for non-destructive mass sensing |
US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
DE60139110D1 (en) | 2000-01-10 | 2009-08-13 | Maxygen Holdings Ltd | G-CSF CONJUGATES |
GB0003935D0 (en) * | 2000-02-08 | 2000-04-12 | King S College London | Formulation for dry powder inhaler |
US7507687B2 (en) * | 2000-03-22 | 2009-03-24 | Cabot Corporation | Electrocatalyst powders, methods for producing powder and devices fabricated from same |
MY136453A (en) * | 2000-04-27 | 2008-10-31 | Philip Morris Usa Inc | "improved method and apparatus for generating an aerosol" |
CA2382133C (en) | 2000-05-10 | 2010-11-23 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
US20030003057A1 (en) * | 2000-07-07 | 2003-01-02 | Jeffry Weers | Methods for administering leuprolide by inhalation |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US7575761B2 (en) | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics |
WO2002009669A2 (en) * | 2000-08-01 | 2002-02-07 | Inhale Therapeutic Systems, Inc. | Apparatus and process to produce particles having a narrow size distribution and particles made thereby |
US20020036154A1 (en) * | 2000-08-10 | 2002-03-28 | Ramaswamy Murari | Solid pharmaceutical dosage formulation of hydrophobic drugs |
US6756062B2 (en) | 2000-11-03 | 2004-06-29 | Board Of Regents University Of Texas System | Preparation of drug particles using evaporation precipitation into aqueous solutions |
US8551526B2 (en) * | 2000-11-03 | 2013-10-08 | Board Of Regents, The University Of Texas System | Preparation of drug particles using evaporation precipitation into aqueous solutions |
GB0027357D0 (en) | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
US6767637B2 (en) * | 2000-12-13 | 2004-07-27 | Purdue Research Foundation | Microencapsulation using ultrasonic atomizers |
ATE361057T1 (en) * | 2000-12-21 | 2007-05-15 | Alrise Biosystems Gmbh | METHOD COMPRISING AN INDUCED PHASE TRANSITION FOR PRODUCING MICROPARTICLES CONTAINING HYDROPHOBIC ACTIVE INGREDIENTS |
WO2002054868A2 (en) * | 2000-12-21 | 2002-07-18 | Inhale Therapeutic Syst | Pulmonary delivery of polyene antifungal agents |
US6501052B2 (en) | 2000-12-22 | 2002-12-31 | Chrysalis Technologies Incorporated | Aerosol generator having multiple heating zones and methods of use thereof |
US6701921B2 (en) | 2000-12-22 | 2004-03-09 | Chrysalis Technologies Incorporated | Aerosol generator having heater in multilayered composite and method of use thereof |
US6491233B2 (en) | 2000-12-22 | 2002-12-10 | Chrysalis Technologies Incorporated | Vapor driven aerosol generator and method of use thereof |
US6681998B2 (en) | 2000-12-22 | 2004-01-27 | Chrysalis Technologies Incorporated | Aerosol generator having inductive heater and method of use thereof |
US6799572B2 (en) | 2000-12-22 | 2004-10-05 | Chrysalis Technologies Incorporated | Disposable aerosol generator system and methods for administering the aerosol |
US7077130B2 (en) * | 2000-12-22 | 2006-07-18 | Chrysalis Technologies Incorporated | Disposable inhaler system |
AU2002230993B2 (en) * | 2000-12-29 | 2006-02-02 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
US20020141946A1 (en) * | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
DE60232434D1 (en) | 2001-02-27 | 2009-07-09 | Maxygen Aps | NEW INTERFERON-BETA-LIKE MOLECULES |
US20030157170A1 (en) * | 2001-03-13 | 2003-08-21 | Richard Liggins | Micellar drug delivery vehicles and precursors thereto and uses thereof |
WO2002072150A2 (en) * | 2001-03-13 | 2002-09-19 | Angiotech Pharmaceuticals Inc. | Micellar drug delivery vehicles and uses thereof |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
EP1411986B1 (en) * | 2001-07-30 | 2008-03-12 | DSM IP Assets B.V. | Composition comprising epigallocatechin gallate |
JP4644397B2 (en) * | 2001-09-05 | 2011-03-02 | 信越化学工業株式会社 | Method for producing pharmaceutical solid preparation containing poorly soluble drug |
US6568390B2 (en) | 2001-09-21 | 2003-05-27 | Chrysalis Technologies Incorporated | Dual capillary fluid vaporizing device |
US6640050B2 (en) | 2001-09-21 | 2003-10-28 | Chrysalis Technologies Incorporated | Fluid vaporizing device having controlled temperature profile heater/capillary tube |
AU2002342241B2 (en) * | 2001-11-01 | 2007-07-19 | Novartis Ag | Spray drying methods and compositions thereof |
CA2465675C (en) | 2001-11-20 | 2008-06-10 | Advanced Inhalation Research, Inc. | Improved particulate compositions for pulmonary delivery |
US20030099601A1 (en) * | 2001-11-27 | 2003-05-29 | Gordon Marc S. | Inhalation lung surfactant therapy |
US6804458B2 (en) * | 2001-12-06 | 2004-10-12 | Chrysalis Technologies Incorporated | Aerosol generator having heater arranged to vaporize fluid in fluid passage between bonded layers of laminate |
US6681769B2 (en) | 2001-12-06 | 2004-01-27 | Crysalis Technologies Incorporated | Aerosol generator having a multiple path heater arrangement and method of use thereof |
ES2364636T3 (en) | 2001-12-19 | 2011-09-08 | Novartis Ag | PULMONARY ADMINISTRATION OF AMINOGLUCOSIDS. |
US6701922B2 (en) | 2001-12-20 | 2004-03-09 | Chrysalis Technologies Incorporated | Mouthpiece entrainment airflow control for aerosol generators |
US20040014679A1 (en) * | 2002-02-20 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof |
US7008644B2 (en) * | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
JP2005521695A (en) * | 2002-03-20 | 2005-07-21 | アドバンスト インハレーション リサーチ,インコーポレイテッド | Method of administering growth hormone by pulmonary delivery |
US20050163725A1 (en) * | 2002-03-20 | 2005-07-28 | Blizzard Charles D. | Method for administration of growth hormone via pulmonary delivery |
JP4681231B2 (en) | 2002-03-20 | 2011-05-11 | マンカインド コーポレイション | Inhaler |
IL164152A0 (en) * | 2002-03-26 | 2005-12-18 | Teva Pharma | Drug microparticles |
MXPA04010560A (en) * | 2002-04-25 | 2005-08-15 | Scripps Research Inst | Treatment and prevention of pulmonary conditions. |
GB0216562D0 (en) | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
US6919348B2 (en) | 2002-05-02 | 2005-07-19 | Edward T. Wei | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
US6991800B2 (en) * | 2002-06-13 | 2006-01-31 | Vicuron Pharmaceuticals Inc. | Antifungal parenteral products |
US7794743B2 (en) | 2002-06-21 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of making the same |
US7033602B1 (en) | 2002-06-21 | 2006-04-25 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of coating implantable medical devices |
US8506617B1 (en) | 2002-06-21 | 2013-08-13 | Advanced Cardiovascular Systems, Inc. | Micronized peptide coated stent |
US7056523B1 (en) | 2002-06-21 | 2006-06-06 | Advanced Cardiovascular Systems, Inc. | Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine |
US7217426B1 (en) | 2002-06-21 | 2007-05-15 | Advanced Cardiovascular Systems, Inc. | Coatings containing polycationic peptides for cardiovascular therapy |
DE10234165B4 (en) * | 2002-07-26 | 2008-01-03 | Advanced Micro Devices, Inc., Sunnyvale | A method of filling a trench formed in a substrate with an insulating material |
US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
GB0219512D0 (en) * | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Inhalation compositions with high drug ratios |
GB0219511D0 (en) * | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Method of preparing dry powder inhalation compositions |
US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
KR20100107083A (en) * | 2002-12-17 | 2010-10-04 | 메디뮨 엘엘씨 | High pressure spray-dry of bioactive materials |
US6962006B2 (en) * | 2002-12-19 | 2005-11-08 | Acusphere, Inc. | Methods and apparatus for making particles using spray dryer and in-line jet mill |
WO2004057959A2 (en) | 2002-12-20 | 2004-07-15 | Generipharm, Inc. | Intracutaneous injection |
MXPA05007154A (en) * | 2002-12-30 | 2005-09-21 | Nektar Therapeutics | Prefilming atomizer. |
KR20050095838A (en) * | 2002-12-31 | 2005-10-04 | 넥타르 테라퓨틱스 | Pharmaceutical formulation with an insoluble active agent for pulmonary administration |
EP1581182A2 (en) * | 2002-12-31 | 2005-10-05 | Nektar Therapeutics | Aerosolizable pharmaceutical formulation for fungal infection therapy |
SE0300514D0 (en) * | 2003-02-26 | 2003-02-26 | Astrazeneca Ab | Powder generating apparatus and methods |
CA2519228C (en) * | 2003-03-20 | 2014-10-14 | Galephar M/F | Improved dry powder inhaler system |
WO2004091577A1 (en) * | 2003-04-17 | 2004-10-28 | Porten Pharmaceutical Ab | Composition, method and pharmaceutical preparation for pharmaceutical spray suspensions |
KR101511196B1 (en) * | 2003-05-28 | 2015-04-10 | 노바르티스 아게 | Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat |
TWI359675B (en) * | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
US20050043247A1 (en) * | 2003-08-18 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative |
DE10339197A1 (en) * | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried amorphous powder with low residual moisture and good storage stability |
GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
US7413690B1 (en) | 2003-10-29 | 2008-08-19 | The University Of Mississippi | Process and apparatus for producing spherical pellets using molten solid matrices |
US20050214224A1 (en) * | 2003-11-04 | 2005-09-29 | Nektar Therapeutics | Lipid formulations for spontaneous drug encapsulation |
SE0303269L (en) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Medical product |
CA2549160A1 (en) * | 2003-12-04 | 2005-06-23 | The Scripps Research Institute | Treatment and preventions of asthma |
US20050238732A1 (en) * | 2003-12-19 | 2005-10-27 | Kaitao Lu | Carbonated germicide with pressure control |
US20050136118A1 (en) * | 2003-12-19 | 2005-06-23 | Wu Su-Syin S. | Distribution and preparation of germicidal compositions |
ITMI20040795A1 (en) * | 2004-04-23 | 2004-07-23 | Eratech S R L | DRY SOLID PHARMACEUTICAL COMPOSITION ON ITS STABLE WATER PREPARATION AND SUSPENSION PROCESS OBTAINED BY ITSELF |
CN101442989B (en) * | 2004-06-21 | 2013-04-03 | 诺瓦帝斯公司 | Compositions comprising amphotericin B |
US8513204B2 (en) * | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
BRPI0514263B8 (en) | 2004-08-20 | 2021-05-25 | Mannkind Corp | method for the synthesis of n-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine n-protected |
KR101306384B1 (en) | 2004-08-23 | 2013-09-09 | 맨카인드 코포레이션 | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
GB0427568D0 (en) * | 2004-12-16 | 2005-01-19 | Resolution Chemicals Ltd | Particle-size reduction apparatus, and the use thereof |
PT1855652E (en) * | 2005-01-28 | 2016-01-26 | Bend Res Inc | Drying of drug-containing particles |
US20070148233A1 (en) * | 2005-12-28 | 2007-06-28 | Lerner E I | Pharmaceutical formulations of fenofibrate having improved bioavailability |
UA95446C2 (en) | 2005-05-04 | 2011-08-10 | Іллюміджен Байосайєнсіз, Інк. | Mutations in oas1 genes |
EP1893182B8 (en) * | 2005-05-26 | 2012-04-04 | Teva Women's Health, Inc. | Oral dosage forms comprising progesterone and method of making and using the same |
US9101949B2 (en) | 2005-08-04 | 2015-08-11 | Eilaz Babaev | Ultrasonic atomization and/or seperation system |
US20070031611A1 (en) * | 2005-08-04 | 2007-02-08 | Babaev Eilaz P | Ultrasound medical stent coating method and device |
US7896539B2 (en) | 2005-08-16 | 2011-03-01 | Bacoustics, Llc | Ultrasound apparatus and methods for mixing liquids and coating stents |
WO2007027574A2 (en) * | 2005-08-29 | 2007-03-08 | Palatin Technologies, Inc. | Cyclic peptide isolation by spray drying |
EP1928423B1 (en) | 2005-09-14 | 2015-12-09 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
ES2327775T3 (en) * | 2005-12-09 | 2009-11-03 | Teva Pharmaceutical Industries, Ltd. | DISPERSIONS AND WATER SOLUTIONS OF DIFFICULT COMPOUNDS TO DISSOLVE AND PROCEDURES FOR THEIR PREPARATION. |
WO2007098500A2 (en) | 2006-02-22 | 2007-08-30 | Mannkind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
JP2009532489A (en) * | 2006-04-03 | 2009-09-10 | テバ ファーマシューティカル インダストリーズ リミティド | Drug fine particles |
GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
PT2043610E (en) * | 2006-07-21 | 2015-10-22 | Bend Res Inc | Drying of drug-containing particles |
EP1925296A1 (en) * | 2006-11-22 | 2008-05-28 | Boehringer Ingelheim Pharma GmbH & Co. KG | Stable powder formulation containing a new antichinolinergic agent |
WO2008062908A1 (en) * | 2006-11-24 | 2008-05-29 | Canon Kabushiki Kaisha | Method for producing particles and particles |
US7985058B2 (en) * | 2007-01-12 | 2011-07-26 | Mark Gray | Method and apparatus for making uniformly sized particles |
US8415390B2 (en) | 2008-05-30 | 2013-04-09 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
US20090105490A1 (en) * | 2007-07-12 | 2009-04-23 | Nurit Perlman | Polymorphic forms of ramelteon and processes for preparation thereof |
US7753285B2 (en) | 2007-07-13 | 2010-07-13 | Bacoustics, Llc | Echoing ultrasound atomization and/or mixing system |
US7780095B2 (en) | 2007-07-13 | 2010-08-24 | Bacoustics, Llc | Ultrasound pumping apparatus |
US8273561B2 (en) | 2007-10-05 | 2012-09-25 | Nuron Biotech, Inc. | High pressure treatment of aggregated interferons |
WO2009118356A2 (en) * | 2008-03-25 | 2009-10-01 | Formac Pharmaceuticals N.V. | Preparation method for solid disupersions |
MX2010012452A (en) | 2008-05-15 | 2011-03-15 | Novartis Ag Star | Pulmonary delivery of a fluoroquinolone. |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
CA2982550C (en) | 2008-06-13 | 2020-08-25 | Mannkind Corporation | A dry powder inhaler and system for drug delivery |
CN102065942B (en) | 2008-06-20 | 2013-12-11 | 曼金德公司 | An interactive apparatus and method for real-time profiling of inhalation efforts |
JP2010028022A (en) * | 2008-07-24 | 2010-02-04 | Mitsubishi Electric Corp | Additive dissolving device |
TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
GB0814953D0 (en) * | 2008-08-18 | 2008-09-24 | Unilever Plc | Improvements relating to nanodisperse compositions |
US20110166063A1 (en) | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
ES2531009T3 (en) | 2008-12-29 | 2015-03-09 | Mannkind Corp | Dicetopiperazine substituted analogs for use as agents for drug administration |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
WO2010085780A1 (en) * | 2009-01-26 | 2010-07-29 | Teva Pharmaceutical Industries Ltd. | Processes for coating a carrier with microparticles |
US20100209475A1 (en) * | 2009-02-19 | 2010-08-19 | Biomet Manufacturing Corp. | Medical implants having a drug delivery coating |
PL2405963T3 (en) | 2009-03-11 | 2014-04-30 | Mannkind Corp | Apparatus, system and method for measuring resistance of an inhaler |
CA2755809C (en) | 2009-03-18 | 2014-02-18 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
JP5908397B2 (en) | 2009-06-09 | 2016-04-26 | デフィルス、インコーポレイテッドDefyrus, Inc. | Interferon administration to prevent or treat pathogen infection |
ES2943333T3 (en) | 2009-06-12 | 2023-06-12 | Mannkind Corp | Diketopiperazine microparticles with defined surface areas |
EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
US20110262502A1 (en) * | 2010-02-08 | 2011-10-27 | Prairie Pharmaceuticals LLC | Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc) |
EP2538923A2 (en) * | 2010-02-22 | 2013-01-02 | Lupin Limited | Taste-masked powder for suspension compositions of methylprednisolone |
EP2575710A1 (en) * | 2010-06-07 | 2013-04-10 | Cva Technologies, LLC | Methods and systems for cerebral cooling |
WO2011154014A1 (en) * | 2010-06-11 | 2011-12-15 | Gea Process Engineering A/S | Controlled humidity drying |
AU2011271097B2 (en) | 2010-06-21 | 2014-11-27 | Mannkind Corporation | Dry powder drug delivery system and methods |
WO2012012460A1 (en) | 2010-07-19 | 2012-01-26 | Xeris Pharmaceuticals, Inc. | Stable glucagon formulations for the treatment of hypoglycemia |
CA2809489C (en) | 2010-09-24 | 2017-10-24 | University Of Florida Research Foundation, Inc. | For improving health of subjects with villous atrophy |
US8939388B1 (en) | 2010-09-27 | 2015-01-27 | ZoomEssence, Inc. | Methods and apparatus for low heat spray drying |
US9332776B1 (en) | 2010-09-27 | 2016-05-10 | ZoomEssence, Inc. | Methods and apparatus for low heat spray drying |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
DK2661254T3 (en) | 2011-01-05 | 2017-11-06 | Hospira Inc | SPRAY DRYING VANCOMYCIN |
MX350838B (en) | 2011-02-11 | 2017-09-18 | Grain Proc Corporation * | Salt composition. |
EP3225235B1 (en) | 2011-03-10 | 2020-12-16 | Xeris Pharmaceuticals, Inc. | Stable peptide formulations for parenteral injection |
CN105853348B (en) | 2011-03-10 | 2019-08-30 | Xeris药物公司 | Parenteral injection stablizing solution |
CN103826988B (en) | 2011-04-01 | 2016-03-09 | 曼金德公司 | For the blister package of pharmaceutical kit |
CA2754237A1 (en) | 2011-05-27 | 2012-11-27 | The Regents Of The University Of California | Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
JP6018640B2 (en) | 2011-10-24 | 2016-11-02 | マンカインド コーポレイション | Analgesic composition effective for alleviating pain, and dry powder and dry powder drug delivery system comprising the composition |
EP2773331B1 (en) | 2011-10-31 | 2016-02-10 | Xeris Pharmaceuticals, Inc. | Formulations for the treatment of diabetes |
US9603907B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Dry powder formulations of dNase I |
IN2012DE00674A (en) | 2012-03-07 | 2015-08-21 | Nat Inst Of Pharmaceutical Education And Res Niper | |
US10086007B2 (en) | 2012-04-05 | 2018-10-02 | University Of Florida Research Foundation, Incorporated | Materials and methods for treatment of cystic fibrosis and for induction of ion secretion |
US8753643B1 (en) | 2012-04-11 | 2014-06-17 | Life-Science Innovations, Llc | Spray dried compositions and methods of use |
CA2869849A1 (en) | 2012-04-13 | 2013-10-17 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate |
US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
WO2014073542A1 (en) * | 2012-11-07 | 2014-05-15 | 理研ビタミン株式会社 | Powdered plant sterol composition and production method therefor |
BR112015010601B1 (en) * | 2012-11-09 | 2022-07-19 | Civitas Therapeutics, Inc. | PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOSITION |
US9956287B2 (en) | 2013-02-06 | 2018-05-01 | Perosphere Inc. | Stable glucagon formulations |
US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
US10350185B2 (en) | 2013-03-11 | 2019-07-16 | University Of Florida Research Foundation, Incorporated | Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications |
KR102391750B1 (en) | 2013-03-15 | 2022-04-28 | 맨카인드 코포레이션 | Microcrystalline diketopiperazine compositions and methods |
CN105451716A (en) | 2013-07-18 | 2016-03-30 | 曼金德公司 | Heat-stable dry powder pharmaceutical compositions and methods |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
WO2016022831A1 (en) | 2014-08-06 | 2016-02-11 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US20170304459A1 (en) | 2014-10-10 | 2017-10-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
US11364203B2 (en) | 2014-10-31 | 2022-06-21 | Bend Reserch, Inc. | Process for forming active domains dispersed in a matrix |
CN107106527B (en) | 2014-11-24 | 2020-11-24 | 恩特林斯科健康解决方案股份公司 | Amino acid composition for treating disease symptoms |
MX2017008567A (en) | 2015-01-04 | 2018-04-26 | Protalix Ltd | Modified dnase and uses thereof. |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
WO2016196976A1 (en) | 2015-06-04 | 2016-12-08 | Xeris Pharmaceuticals, Inc. | Glucagon delivery apparatuses and related methods |
WO2016201248A1 (en) | 2015-06-10 | 2016-12-15 | Xeris Pharmaceuticals, Inc. | Use of low dose glucagon |
RU2731212C2 (en) * | 2015-09-09 | 2020-08-31 | Новартис Аг | Directed delivery of spray-dried compositions into the lungs |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
PT108885B (en) | 2015-10-12 | 2019-02-13 | Hovione Farm S A | METHOD OF PRODUCTION OF INHALABLE COMPOSITE PARTICULARS USING A THREE FLUID ATOMIZER |
JP2019509985A (en) | 2016-02-01 | 2019-04-11 | インカーダ セラピューティクス, インコーポレイテッド | Combining electronic monitoring with inhalation medication to manage cardiac arrhythmias including atrial fibrillation |
CA3031533A1 (en) * | 2016-07-25 | 2018-02-01 | Ebbu Inc. | New cannabis tablet formulations and compositions and methods of making the same |
BR112019006742A2 (en) | 2016-10-04 | 2019-09-03 | Entrinsic Health Solutions Inc | amino acid compositions and uses thereof |
CA3078723A1 (en) | 2016-11-28 | 2018-05-31 | Nachiappan Chidambaram | Oral testosterone undecanoate therapy |
EP3621616A4 (en) | 2017-05-10 | 2021-01-13 | InCarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
AU2018273887B2 (en) | 2017-05-22 | 2022-09-08 | Insmed Incorporated | Lipo-glycopeptide cleavable derivatives and uses thereof |
KR20240036128A (en) | 2017-06-02 | 2024-03-19 | 엑스에리스 파머수티클스, 인크. | Precipitation resistant small molecule drug formulations |
US10155234B1 (en) | 2017-08-04 | 2018-12-18 | ZoomEssence, Inc. | Ultrahigh efficiency spray drying apparatus and process |
CA3071115C (en) | 2017-08-04 | 2022-06-21 | ZoomEssence, Inc. | Ultrahigh efficiency spray drying apparatus and process |
US10486173B2 (en) | 2017-08-04 | 2019-11-26 | ZoomEssence, Inc. | Ultrahigh efficiency spray drying apparatus and process |
US9861945B1 (en) | 2017-08-04 | 2018-01-09 | ZoomEssence, Inc. | Ultrahigh efficiency spray drying apparatus and process |
US9993787B1 (en) | 2017-08-04 | 2018-06-12 | ZoomEssence, Inc. | Ultrahigh efficiency spray drying apparatus and process |
CN111770740A (en) | 2018-01-08 | 2020-10-13 | 维沃尼克斯股份有限公司 | System and method for cooling the brain of a human body |
US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
US10569244B2 (en) | 2018-04-28 | 2020-02-25 | ZoomEssence, Inc. | Low temperature spray drying of carrier-free compositions |
CN114072136A (en) | 2019-04-29 | 2022-02-18 | 英斯梅德股份有限公司 | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
EP4138884A1 (en) | 2020-04-20 | 2023-03-01 | Sorrento Therapeutics, Inc. | Pulmonary administration of ace2 polypeptides |
KR20230104160A (en) | 2020-10-07 | 2023-07-07 | 프로탈릭스 리미티드 | long-acting deoxyribonuclease (DNASE) |
WO2023150747A1 (en) | 2022-02-07 | 2023-08-10 | Insmed Incorporated | Dry powder compositions of bedaquiline and salts and methods of use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4540602A (en) * | 1979-04-13 | 1985-09-10 | Freund Industry Company, Limited | Process for the preparation of activated pharmaceutical compositions |
US4590206A (en) * | 1981-07-24 | 1986-05-20 | Fisons Plc | Inhalation pharmaceuticals |
US5376386A (en) * | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722941A (en) * | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
JPS6034925B2 (en) | 1979-07-31 | 1985-08-12 | 帝人株式会社 | Long-acting nasal preparation and its manufacturing method |
JPS607965B2 (en) | 1980-08-07 | 1985-02-28 | 帝人株式会社 | Method for manufacturing powder for nasal mucosal administration |
US5260306A (en) * | 1981-07-24 | 1993-11-09 | Fisons Plc | Inhalation pharmaceuticals |
JPS5921613A (en) * | 1982-07-28 | 1984-02-03 | Takeda Chem Ind Ltd | Pharmaceutical preparation for rectum administration |
US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
NL192564C (en) | 1982-10-08 | 1997-10-03 | Glaxo Group Ltd | Device for administering medicaments to patients. |
US4486435A (en) * | 1983-05-16 | 1984-12-04 | Basf Wyandotte Corporation | Spray-dried vitamin powders using hydrophobic silica |
PT83094B (en) | 1985-07-30 | 1993-07-30 | Glaxo Group Ltd | DEVICES PROPER FOR THE ADMINISTRATION OF MEDICINES TO PATIENTS |
JP2562624B2 (en) * | 1986-11-07 | 1996-12-11 | 昭和電工株式会社 | Water-soluble microcapsule and liquid detergent composition |
SE8701479L (en) * | 1987-04-09 | 1988-10-10 | Carbomatrix Ab | METHOD FOR CONTAINING BIOLOGICALLY EFFECTIVE PREPARATIONS AND USE THEREOF |
CH672048A5 (en) * | 1987-09-16 | 1989-10-31 | Nestle Sa | |
US4999189A (en) * | 1988-11-14 | 1991-03-12 | Schering Corporation | Sustained release oral suspensions |
US5011678A (en) * | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
US5130137A (en) * | 1989-08-09 | 1992-07-14 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders |
GB8921222D0 (en) * | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
GB9001635D0 (en) | 1990-01-24 | 1990-03-21 | Ganderton David | Aerosol carriers |
JPH05507090A (en) * | 1990-05-08 | 1993-10-14 | リポサーム テクノロジー インコーポレイテッド | Direct spray-dried drug/lipid powder compositions |
US5000888A (en) * | 1990-05-23 | 1991-03-19 | Basf Corporation | Process for spray drying riboflavin to produce a granulate product having low binder content |
JP3181392B2 (en) * | 1991-08-02 | 2001-07-03 | 株式会社ヤトロン | Stable aqueous transparent liquid, method for producing the same, and freeze-dried powder |
CA2079509C (en) * | 1991-10-01 | 2002-05-14 | Shigeyuki Takada | Prolonged release microparticle preparation and production of the same |
DE69332240T2 (en) * | 1992-06-12 | 2003-04-10 | Teijin Ltd | ULTRA FINE POWDER FOR INHALATION AND PRODUCTION |
AU4198793A (en) * | 1992-07-24 | 1994-01-27 | Takeda Chemical Industries Ltd. | Microparticle preparation and production thereof |
ATE220327T1 (en) * | 1992-09-29 | 2002-07-15 | Inhale Therapeutic Syst | PULMONARY RELEASE OF ACTIVE FRAGMENTS OF THE PARATHORMONE |
WO1994009898A1 (en) | 1992-10-26 | 1994-05-11 | Schwarz Pharma Ag | Method of manufacturing microcapsules |
AU660852B2 (en) * | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5773026A (en) * | 1993-03-22 | 1998-06-30 | Betatene Limited | Aqueous formulations of water-insoluble therapeutic agent comprising carotenoids and/or tocopherols |
US5994314A (en) * | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
US5510391A (en) * | 1993-10-22 | 1996-04-23 | Mayapple Holdings, Llc | Method of treating blood vessel disorders of the skin using vitamin K |
EP0655237A1 (en) * | 1993-11-27 | 1995-05-31 | Hoechst Aktiengesellschaft | Medicinal aerosol formulation |
EP0748225B1 (en) * | 1994-03-04 | 2004-06-09 | Genentech, Inc. | PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION |
EP0748213B1 (en) * | 1994-03-07 | 2004-04-14 | Nektar Therapeutics | Methods and compositions for pulmonary delivery of insulin |
AU697676B2 (en) | 1994-09-21 | 1998-10-15 | Nektar Therapeutics | Apparatus and methods for dispersing dry powder medicaments |
JPH0892098A (en) * | 1994-09-27 | 1996-04-09 | Teijin Ltd | Therapeutic medicine for consumption |
CA2199954A1 (en) * | 1994-09-29 | 1996-04-04 | Andrew Derek Sutton | Spray-dried microparticles as therapeutic vehicles |
US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
JPH08301762A (en) * | 1995-05-12 | 1996-11-19 | Teijin Ltd | Agent for treatment of lung cancer |
CA2222811C (en) * | 1995-06-01 | 2008-09-30 | G.D. Searle & Co. | Stabilized solid dispersions of misoprostol |
US5667806A (en) * | 1995-06-07 | 1997-09-16 | Emisphere Technologies, Inc. | Spray drying method and apparatus |
DE59706180D1 (en) * | 1996-01-24 | 2002-03-14 | Byk Gulden Lomberg Chem Fab | METHOD FOR PRODUCING POWDERED LUNG SURFACTANT PREPARATIONS |
GB9606677D0 (en) * | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
EP0971698A4 (en) * | 1996-12-31 | 2006-07-26 | Nektar Therapeutics | Aerosolized hydrophobic drug |
-
1997
- 1997-12-29 EP EP97954799A patent/EP0971698A4/en not_active Withdrawn
- 1997-12-29 WO PCT/US1997/023904 patent/WO1998029141A1/en active Application Filing
- 1997-12-29 WO PCT/US1997/023905 patent/WO1998029098A1/en active Application Filing
- 1997-12-29 AU AU58068/98A patent/AU5806898A/en not_active Abandoned
- 1997-12-29 WO PCT/US1997/023903 patent/WO1998029140A1/en active Application Filing
- 1997-12-29 JP JP53022598A patent/JP2001507701A/en active Pending
- 1997-12-29 EP EP97954240A patent/EP0951300A4/en not_active Ceased
- 1997-12-29 WO PCT/US1997/023902 patent/WO1998029096A1/en active Application Filing
- 1997-12-29 US US08/999,095 patent/US6001336A/en not_active Expired - Lifetime
- 1997-12-29 AU AU57197/98A patent/AU5719798A/en not_active Abandoned
- 1997-12-29 US US08/999,104 patent/US5985248A/en not_active Expired - Lifetime
- 1997-12-29 EP EP97953453A patent/EP0952821A4/en not_active Ceased
- 1997-12-29 JP JP53022698A patent/JP2001507702A/en not_active Ceased
- 1997-12-29 JP JP53022398A patent/JP2001507700A/en active Pending
- 1997-12-29 AU AU58069/98A patent/AU5806998A/en not_active Abandoned
- 1997-12-29 US US08/999,097 patent/US6077543A/en not_active Expired - Lifetime
- 1997-12-29 US US08/999,100 patent/US5976574A/en not_active Expired - Lifetime
- 1997-12-29 AU AU60140/98A patent/AU6014098A/en not_active Abandoned
-
2000
- 2000-03-17 US US09/528,758 patent/US6365190B1/en not_active Expired - Lifetime
-
2002
- 2002-02-08 US US10/072,407 patent/US6572893B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4540602A (en) * | 1979-04-13 | 1985-09-10 | Freund Industry Company, Limited | Process for the preparation of activated pharmaceutical compositions |
US4590206A (en) * | 1981-07-24 | 1986-05-20 | Fisons Plc | Inhalation pharmaceuticals |
US5376386A (en) * | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
Non-Patent Citations (1)
Title |
---|
See also references of EP0951300A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6315983B1 (en) | 1996-01-24 | 2001-11-13 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Process for the production of powdered pulmonary surfactant preparations |
US6630121B1 (en) | 1999-06-09 | 2003-10-07 | The Regents Of The University Of Colorado | Supercritical fluid-assisted nebulization and bubble drying |
US6669960B2 (en) | 1999-12-21 | 2003-12-30 | Rxkinetix, Inc. | Particulate drug-containing products and method of manufacture |
US6761909B1 (en) | 1999-12-21 | 2004-07-13 | Rxkinetix, Inc. | Particulate insulin-containing products and method of manufacture |
US7125566B2 (en) | 1999-12-21 | 2006-10-24 | Rxkinetix, Inc. | Particulate drug-containing products and method of manufacture |
US10806770B2 (en) | 2014-10-31 | 2020-10-20 | Monash University | Powder formulation |
Also Published As
Publication number | Publication date |
---|---|
AU5806998A (en) | 1998-07-31 |
US20020132011A1 (en) | 2002-09-19 |
AU5806898A (en) | 1998-07-31 |
US6572893B2 (en) | 2003-06-03 |
US6001336A (en) | 1999-12-14 |
WO1998029140A1 (en) | 1998-07-09 |
EP0951300A1 (en) | 1999-10-27 |
EP0952821A4 (en) | 2006-07-26 |
US5976574A (en) | 1999-11-02 |
EP0951300A4 (en) | 2006-07-26 |
US6077543A (en) | 2000-06-20 |
WO1998029098A1 (en) | 1998-07-09 |
US6365190B1 (en) | 2002-04-02 |
AU6014098A (en) | 1998-07-31 |
WO1998029096A1 (en) | 1998-07-09 |
US5985248A (en) | 1999-11-16 |
JP2001507700A (en) | 2001-06-12 |
AU5719798A (en) | 1998-07-31 |
JP2001507702A (en) | 2001-06-12 |
EP0952821A1 (en) | 1999-11-03 |
EP0971698A1 (en) | 2000-01-19 |
JP2001507701A (en) | 2001-06-12 |
EP0971698A4 (en) | 2006-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5985248A (en) | Processes for spray drying solutions of hydrophobic drugs and compositions thereof | |
US8802149B2 (en) | Systems and processes for spray drying hydrophobic and hydrophilic components | |
US8668934B2 (en) | Pharmaceutical formulation comprising a water-insoluble active agent | |
KR100951750B1 (en) | Spray drying methods and compositions thereof | |
US7625865B2 (en) | Insulin highly respirable microparticles | |
Klingler et al. | Insulin-micro-and nanoparticles for pulmonary delivery | |
KR20020060218A (en) | Dry powder compositions having improved dispersivity | |
JPH11501657A (en) | Powder type pharmacological composition having improved dispersibility | |
US20150202156A1 (en) | Dry powder pharmaceutical composition, its preparation process and stable aqueous suspension obtained from such composition | |
EP1971326A2 (en) | Respirable powders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 530225 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997954240 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997954240 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |